SubHero Banner

Tecvayli(teclistamab-cqyv) – New drug approval

October 25, 2022 - Janssen announced the FDA approval of Tecvayli (teclistamab-cqyv), for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

Download PDF